265 related articles for article (PubMed ID: 30646796)
1. Differential clinical significance of pre-, interim-, and post-treatment plasma Epstein-Barr virus DNA load in NK/T-cell lymphoma treated with P-GEMOX protocol.
Wang XX; Li PF; Bai B; Gao Y; Rong QX; Cai QQ; Lin SX; Zhang YJ; Li ZM; Jiang WQ; Huang HQ
Leuk Lymphoma; 2019 Aug; 60(8):1917-1925. PubMed ID: 30646796
[TBL] [Abstract][Full Text] [Related]
2. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
Wang L; Wang H; Wang JH; Xia ZJ; Lu Y; Huang HQ; Jiang WQ; Zhang YJ
Oncotarget; 2015 Oct; 6(30):30317-26. PubMed ID: 26210287
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma.
Wei W; Wu P; Li L; Zhang ZH
Hematology; 2017 Jul; 22(6):320-329. PubMed ID: 27917702
[TBL] [Abstract][Full Text] [Related]
4. Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma.
Cho J; Kim SJ; Park S; Yoo KH; Ki CS; Ko Y; Kim WS
Ann Hematol; 2018 Aug; 97(8):1427-1436. PubMed ID: 29627879
[TBL] [Abstract][Full Text] [Related]
5. Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: A multicenter study.
Zhang Y; Ma S; Cai J; Yang Y; Jing H; Shuang Y; Peng Z; Li B; Liu P; Xia Z; Xia Y; Gao Y; Chen D; Lin J; Li Q; Xu S; Xu Q; Zhang H; Huang H; Cai Q
Am J Hematol; 2021 Nov; 96(11):1481-1490. PubMed ID: 34449095
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.
Ito Y; Kimura H; Maeda Y; Hashimoto C; Ishida F; Izutsu K; Fukushima N; Isobe Y; Takizawa J; Hasegawa Y; Kobayashi H; Okamura S; Kobayashi H; Yamaguchi M; Suzumiya J; Hyo R; Nakamura S; Kawa K; Oshimi K; Suzuki R
Clin Cancer Res; 2012 Aug; 18(15):4183-90. PubMed ID: 22675173
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.
Wang JH; Wang L; Liu CC; Xia ZJ; Huang HQ; Lin TY; Jiang WQ; Lu Y
Oncotarget; 2016 May; 7(20):29092-101. PubMed ID: 27093153
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma.
Wang JH; Wang H; Wang YJ; Xia ZJ; Huang HQ; Jiang WQ; Lu Y
Oncotarget; 2016 Jun; 7(23):35412-22. PubMed ID: 27072578
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of patients treated with SVILE
Wei L; Yang L; Ye J; Cong J; Li X; Yao N; Yang J; Cui X; Ding J; Wu Y; Wang J
Cancer Biol Med; 2020 Aug; 17(3):795-804. PubMed ID: 32944407
[No Abstract] [Full Text] [Related]
10. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy.
Wang ZY; Liu QF; Wang H; Jin J; Wang WH; Wang SL; Song YW; Liu YP; Fang H; Ren H; Wu RY; Chen B; Zhang XM; Lu NN; Zhou LQ; Li YX
Blood; 2012 Sep; 120(10):2003-10. PubMed ID: 22826562
[TBL] [Abstract][Full Text] [Related]
11. Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution.
Huang Y; Rao H; Yan S; Wang F; Wu Q; Feng Y; Zhang Y
Ann Hematol; 2017 Aug; 96(8):1331-1342. PubMed ID: 28550598
[TBL] [Abstract][Full Text] [Related]
12. DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients.
Wang X; Hu J; Dong M; Ding M; Zhu L; Wu J; Sun Z; Li X; Zhang L; Li L; Wang X; Fu X; Wang G; Chen Q; Zhang M; Zhang X
Clin Transl Sci; 2021 Jan; 14(1):405-411. PubMed ID: 33045134
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerance of GELOXD/P-GEMOXD in newly diagnosed nasal-type extranodal NK/T-cell lymphoma: A multicenter retrospective study.
Li JW; Li YJ; Zhong MZ; Liu XL; Li J; Li KL; Liu XY; Zhou F; OuYang Z; Sun ZY; Huang LJ; He JQ; Zhou H; Yi PY
Eur J Haematol; 2018 Mar; 100(3):247-256. PubMed ID: 29194798
[TBL] [Abstract][Full Text] [Related]
14. T/NK cell type chronic active Epstein-Barr virus disease in adults: an underlying condition for Epstein-Barr virus-associated T/NK-cell lymphoma.
Isobe Y; Aritaka N; Setoguchi Y; Ito Y; Kimura H; Hamano Y; Sugimoto K; Komatsu N
J Clin Pathol; 2012 Mar; 65(3):278-82. PubMed ID: 22247563
[TBL] [Abstract][Full Text] [Related]
15. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis.
Kim SJ; Choi JY; Hyun SH; Ki CS; Oh D; Ahn YC; Ko YH; Choi S; Jung SH; Khong PL; Tang T; Yan X; Lim ST; Kwong YL; Kim WS;
Lancet Haematol; 2015 Feb; 2(2):e66-74. PubMed ID: 26687611
[TBL] [Abstract][Full Text] [Related]
16. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type.
Suzuki R; Yamaguchi M; Izutsu K; Yamamoto G; Takada K; Harabuchi Y; Isobe Y; Gomyo H; Koike T; Okamoto M; Hyo R; Suzumiya J; Nakamura S; Kawa K; Oshimi K;
Blood; 2011 Dec; 118(23):6018-22. PubMed ID: 21984805
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.
Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL
EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540
[TBL] [Abstract][Full Text] [Related]
18. Dynamic evaluation of the prognostic value of
Xu P; Guo R; You J; Cheng S; Li J; Zhong H; Sun C; Xu H; Huang H; Li B; Zhao W
Ann Hematol; 2021 Apr; 100(4):1039-1047. PubMed ID: 33634350
[TBL] [Abstract][Full Text] [Related]
19. Circulating Epstein-Barr virus-encoded micro-RNAs as potential biomarkers for nasal natural killer/T-cell lymphoma.
Komabayashi Y; Kishibe K; Nagato T; Ueda S; Takahara M; Harabuchi Y
Hematol Oncol; 2017 Dec; 35(4):655-663. PubMed ID: 27709652
[TBL] [Abstract][Full Text] [Related]
20. Persistent peripheral blood EBV-DNA positive with high expression of PD-L1 and upregulation of CD4 + CD25 + T cell ratio in early stage NK/T cell lymphoma patients may predict worse outcome.
Li PF; Mao YZ; Bai B; Gao Y; Zhang YJ; Li ZM; Jiang WQ; Huang HQ
Ann Hematol; 2018 Dec; 97(12):2381-2389. PubMed ID: 30116872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
